Whittier Trust Co. of Nevada Inc. Has $5.49 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Whittier Trust Co. of Nevada Inc. increased its stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 7.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 78,984 shares of the company's stock after buying an additional 5,265 shares during the period. Whittier Trust Co. of Nevada Inc.'s holdings in Novo Nordisk A/S were worth $5,485,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in NVO. Strategic Investment Solutions Inc. IL lifted its holdings in Novo Nordisk A/S by 2,727.3% during the 4th quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock worth $27,000 after buying an additional 300 shares in the last quarter. Copeland Capital Management LLC boosted its holdings in Novo Nordisk A/S by 184.8% in the first quarter. Copeland Capital Management LLC now owns 393 shares of the company's stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. acquired a new stake in Novo Nordisk A/S in the first quarter worth about $27,000. Park Square Financial Group LLC bought a new stake in Novo Nordisk A/S during the 4th quarter worth about $29,000. Finally, Transce3nd LLC acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $33,000. Institutional investors own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on NVO. BNP Paribas began coverage on shares of Novo Nordisk A/S in a research report on Tuesday, April 15th. They issued an "underperform" rating on the stock. Wall Street Zen raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Saturday, June 14th. Guggenheim downgraded shares of Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research note on Thursday, April 17th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Finally, Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $112.00.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock traded down $1.62 on Thursday, hitting $65.42. The stock had a trading volume of 7,316,729 shares, compared to its average volume of 7,362,271. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The stock has a market cap of $292.09 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.29 and a beta of 0.64. The business's 50 day moving average is $70.36 and its two-hundred day moving average is $74.67. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $139.74.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The business had revenue of $11.87 billion during the quarter. Analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.